Chemoradiotherapy, Adjuvant

"Chemoradiotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Combined chemotherapy and radiotherapy given to augment some other form of treatment such as surgery. It is commonly used in the therapy of cancer.

Descriptor ID	D059186
MeSH Number(s)	E02.186.079.500 E02.319.164.500 E02.815.160.500
Concept/Terms	Chemoradiotherapy, Adjuvant Chemoradiotherapy, Adjuvant Adjuvant Chemoradiotherapies Chemoradiotherapies, Adjuvant Adjuvant Radiochemotherapy Adjuvant Radiochemotherapies Radiochemotherapies, Adjuvant Radiochemotherapy, Adjuvant Adjuvant Chemoradiotherapy

Below are MeSH descriptors whose meaning is more general than "Chemoradiotherapy, Adjuvant".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Combined Modality Therapy [E02.186]
Chemoradiotherapy [E02.186.079]
Chemoradiotherapy, Adjuvant [E02.186.079.500]
Drug Therapy [E02.319]
Chemoradiotherapy [E02.319.164]
Chemoradiotherapy, Adjuvant [E02.319.164.500]
Radiotherapy [E02.815]
Chemoradiotherapy [E02.815.160]
Chemoradiotherapy, Adjuvant [E02.815.160.500]

Below are MeSH descriptors whose meaning is related to "Chemoradiotherapy, Adjuvant".

Below are MeSH descriptors whose meaning is more specific than "Chemoradiotherapy, Adjuvant".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Chemoradiotherapy, Adjuvant" by people in this website by year, and whether "Chemoradiotherapy, Adjuvant" was a major or minor topic of these publications.

Bar chart showing 17 publications over 10 distinct years, with a maximum of 3 publications in 2019 and 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2010	1	0	1
2011	1	1	2
2012	1	0	1
2013	1	1	2
2014	2	0	2
2017	0	1	1
2018	0	1	1
2019	1	2	3
2021	0	3	3
2024	0	1	1

Below are the most recent publications written about "Chemoradiotherapy, Adjuvant" by people in Profiles.

Nadeem MS, Ali U, Khan A, Wajid I, Riaz O, Azeem MT. Response of various histological types of locally advanced rectal cancer to neoadjuvant multimodality therapy. J Pak Med Assoc. 2024 Jul; 74(7):1240-1244.

View in: PubMed
Jou J, Charo L, Hom-Tedla M, Coakley K, Binder P, Saenz C, Eskander RN, McHale M, Plaxe S. Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer. Gynecol Oncol. 2021 11; 163(2):299-304.

View in: PubMed
Naffouje SA, Sabesan A, Kim DW, Carballido E, Frakes J, Hodul P, Denbo JW, Malafa M, Fleming J, Hoffe S. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. J Gastrointest Surg. 2022 02; 26(2):376-386.

View in: PubMed
Carey RM, Brody RM, Shimunov D, Shinn JR, Mady LJ, Rajasekaran K, Cannady SB, Lin A, Lukens JN, Bauml JM, Cohen RB, Basu D, O'Malley BW, Weinstein GS, Newman JG. Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS. Laryngoscope. 2021 12; 131(12):E2865-E2873.

View in: PubMed
Spunt SL, Million L, Chi YY, Anderson J, Tian J, Hibbitts E, Coffin C, McCarville MB, Randall RL, Parham DM, Black JO, Kao SC, Hayes-Jordan A, Wolden S, Laurie F, Speights R, Kawashima E, Skapek SX, Meyer W, Pappo AS, Hawkins DS. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study. Lancet Oncol. 2020 01; 21(1):145-161.

View in: PubMed
Margalit O, Shacham-Shmueli E, Lawrence YR, Yang YX, Reiss KA, Golan T, Mamtani R, Halpern N, Aderka D, Giantonio B, Boursi B. Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS. Clin Colorectal Cancer. 2019 09; 18(3):e300-e307.

View in: PubMed
Jayanathan M, Erwin RP, Molacek N, Fluck M, Hunsinger M, Wild J, Arora TK, Shabahang MM, Franko J, Blansfield JA. MAGIC versus MacDonald treatment regimens for gastric cancer: Trends and predictors of multimodal therapy for gastric cancer using?the National Cancer Database. Am J Surg. 2020 01; 219(1):129-135.

View in: PubMed
Jaap K, Fluck M, Hunsinger M, Wild J, Arora T, Shabahang M, Blansfield J. Analyzing the Impact of Compliance with National Guidelines for Pancreatic Cancer Care Using the National Cancer Database. J Gastrointest Surg. 2018 08; 22(8):1358-1364.

View in: PubMed
Tiesi G, Park W, Gunder M, Rubio G, Berger M, Ardalan B, Livingstone A, Franceschi D. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer. J Surg Res. 2017 08; 216:65-72.

View in: PubMed
Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. Ann Thorac Surg. 2015 Jan; 99(1):270-6.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement